文献速递肾移植

EU-TRAIN研究:肾移植排斥无创生物标志物的前瞻性多中心评估

Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN).
PubMed 文献 · Kidney Int · 2024-08-27

结果显示CD4基因表达与排斥显著相关,抗HLA DSA与排斥及抗体介导排斥强相关,其余标志物均无显著关联,且血mRNA和非HLA抗体在标准监测和DSA之外无额外预测价值。

要点

  • CD4基因表达与移植后第一年排斥反应显著相关。
  • 循环抗HLA DSA与排斥显著相关,与抗体介导排斥强相关。
  • 其余18种血mRNA和4种非HLA抗体与排斥无显著关联。

核心结论

  • 血mRNA和非HLA抗体在标准监测参数及循环抗HLA DSA之外,对预测移植后第一年排斥无额外价值。

研究设计与样本

  • 共纳入412例患者,812次活检配对血样本,前瞻性检测19种血mRNA、4种非HLA内皮抗体及循环抗HLA DSA。

主要发现

  • CD4基因表达与排斥反应显著相关。
  • 循环抗HLA DSA与移植排斥显著相关,与抗体介导排斥强相关。
  • AKR1C3、CD3E、CD40、CD8A、CD9、CTLA4、ENTPD1、FOXP3、GZMB、ID3、IL7R、MS4A1、MZB1、POU2AF1、POU2F1、TCL1A、TLR4和TRIB1等mRNA及抗AT1R、抗ETAR、抗C3aR和抗C5aR抗体均与排斥无显著关联。
  • 血mRNA和非HLA抗体未显示超越标准监测参数和循环抗HLA DSA的额外预测价值。

临床怎么用

  • 当前证据不支持将所测血mRNA panel和非HLA抗体常规用于肾移植排斥无创监测。
  • 循环抗HLA DSA仍与排斥及抗体介导排斥显著相关,可结合标准监测评估。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020. We prospectively assessed gene expression levels of 19 blood messenger RNAs, four antibodies targeting non-human leukocyte antigen (HLA) endothelial antigens, together with circulating anti-HLA donor-specific antibodies (DSA). The primary outcome was allograft rejection (antibody-mediated, T cell-mediated, or mixed) in the first year post-transplantation. Overall, 412 patients were included, with 812 biopsies paired with a blood sample. CD4 gene expression was significantly associated with rejection, while circulating anti-HLA DSA had a significant association with allograft rejection and a strong association with antibody-mediated rejection. All other tested biomarkers, including AKR1C3, CD3E, CD40, CD8A, CD9, CTLA4, ENTPD1, FOXP3, GZMB, ID3, IL7R, MS4A1, MZB1, POU2AF1, POU2F1, TCL1A, TLR4, and TRIB1, as well as antibodies against angiotensin II type 1 receptor, endothelin 1 type A receptor, C3a and C5a receptors, did not show significant associations with allograft rejection. The blood messenger RNAs and non-HLA antibodies did not show an additional value beyond standard of care monitoring parameters and circulating anti-HLA DSA to predict allograft rejection in the first year post-transplantation. Thus, our results open avenues for specifically designed studies to demonstrate the clinical relevance and implementation of other candidate non-invasive biomarkers in kidney transplantation practice.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Goutaudier V, Danger R, Catar RA, et al. Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN). Kidney Int. 2024. PMID: 39197587. doi:10.1016/j.kint.2024.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。